Skip to main content
Journal cover image

Neutral effect on markers of heart failure, inflammation, endothelial activation and function, and vagal tone after high-dose HMG-CoA reductase inhibition in non-diabetic patients with non-ischemic cardiomyopathy and average low-density lipoprotein level.

Publication ,  Journal Article
Bleske, BE; Nicklas, JM; Bard, RL; Brook, RD; Gurbel, PA; Bliden, KP; Rajagopalan, S; Pitt, B
Published in: J Am Coll Cardiol
January 17, 2006

OBJECTIVES: This study sought to determine the effect of aggressive 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor (statin) therapy on surrogate markers in non-ischemic cardiomyopathy (NICM) patients and average low-density lipoprotein (LDL) concentrations. BACKGROUND: The effects of statins may well go beyond lipid lowering, and these pleiotropic effects may be of benefit in the treatment of heart failure. METHODS: Fifteen patients with NICM on standard maximized heart failure medication were enrolled in a randomized, double-blinded, placebo-controlled, crossover trial. Patients received 80 mg atorvastatin (ATV) or matching placebo for a 12-week treatment period with a minimum of an 8-week washout period. The following surrogate markers were evaluated: N-terminal-pro brain natriuretic peptide, high-sensitivity C-reactive protein, oxidized LDL antibody, soluble receptor tumor necrosis factor, tumor necrosis factor-alpha, circulating levels of vascular adhesion molecule-1, intercellular adhesion molecule-1, P-selectin, non-invasive endothelial function studies, and heart rate variability. RESULTS: After ATV therapy, there was a significant decrease in LDL concentration from 110 +/- 27 mg/dl to 55 +/- 18 mg/dl (p < 0.05). There were no differences between ATV and placebo with regard to the surrogate markers measured. CONCLUSIONS: Based on these findings, it seems that the administration of high-dose statins to a heart failure population with modest LDL levels and no other indication for statin therapy was neither beneficial nor detrimental as determined by surrogate marker measures. Further studies are needed to determine whether there is an appropriate patient population and optimal dose (LDL concentration) for the treatment of systolic heart failure with statin therapy.

Duke Scholars

Published In

J Am Coll Cardiol

DOI

EISSN

1558-3597

Publication Date

January 17, 2006

Volume

47

Issue

2

Start / End Page

338 / 341

Location

United States

Related Subject Headings

  • Ventricular Remodeling
  • Vascular Cell Adhesion Molecule-1
  • Receptors, Tumor Necrosis Factor
  • Peptide Fragments
  • P-Selectin
  • Natriuretic Peptide, Brain
  • Middle Aged
  • Male
  • Lipoproteins, LDL
  • Intercellular Adhesion Molecule-1
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Bleske, B. E., Nicklas, J. M., Bard, R. L., Brook, R. D., Gurbel, P. A., Bliden, K. P., … Pitt, B. (2006). Neutral effect on markers of heart failure, inflammation, endothelial activation and function, and vagal tone after high-dose HMG-CoA reductase inhibition in non-diabetic patients with non-ischemic cardiomyopathy and average low-density lipoprotein level. J Am Coll Cardiol, 47(2), 338–341. https://doi.org/10.1016/j.jacc.2005.06.087
Bleske, Barry E., John M. Nicklas, Robert L. Bard, Robert D. Brook, Paul A. Gurbel, Kevin P. Bliden, Sanjay Rajagopalan, and Bertram Pitt. “Neutral effect on markers of heart failure, inflammation, endothelial activation and function, and vagal tone after high-dose HMG-CoA reductase inhibition in non-diabetic patients with non-ischemic cardiomyopathy and average low-density lipoprotein level.J Am Coll Cardiol 47, no. 2 (January 17, 2006): 338–41. https://doi.org/10.1016/j.jacc.2005.06.087.
Journal cover image

Published In

J Am Coll Cardiol

DOI

EISSN

1558-3597

Publication Date

January 17, 2006

Volume

47

Issue

2

Start / End Page

338 / 341

Location

United States

Related Subject Headings

  • Ventricular Remodeling
  • Vascular Cell Adhesion Molecule-1
  • Receptors, Tumor Necrosis Factor
  • Peptide Fragments
  • P-Selectin
  • Natriuretic Peptide, Brain
  • Middle Aged
  • Male
  • Lipoproteins, LDL
  • Intercellular Adhesion Molecule-1